The transaction is expected to close before the end of the year. Boston Scientific Corp. expects to record a gain in excess of $500 million upon closing, and total after-tax proceeds are estimated at approximately $1.2 billion.
Under the agreement, Boston Scientific will provide transitional services and products to Stryker. During the transition, products will be sold to Stryker at a cost.
Read the release on Stryker’s acquisition.
Read more coverage on Stryker:
– Stryker Reports a 7% Net Sales Increase for 3Q 2010
– Stryker’s Oren Gelman Discusses Trends Toward Single-Radius Knee Implant Design
– Stryker Acquires Gaymar Industries for $150M
